中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

丙型肝炎病毒小鼠实验模型的研究进展

兰海云 汪爱勤 尹文

兰海云, 汪爱勤, 尹文. 丙型肝炎病毒小鼠实验模型的研究进展[J]. 临床肝胆病杂志, 2011, 27(1): 36-39.
引用本文: 兰海云, 汪爱勤, 尹文. 丙型肝炎病毒小鼠实验模型的研究进展[J]. 临床肝胆病杂志, 2011, 27(1): 36-39.
Lan HaiYun, Wang AiQin, Yin Wen. Advance in the research of experimental mouse model for hepatitis C virus[J]. J Clin Hepatol, 2011, 27(1): 36-39.
Citation: Lan HaiYun, Wang AiQin, Yin Wen. Advance in the research of experimental mouse model for hepatitis C virus[J]. J Clin Hepatol, 2011, 27(1): 36-39.

丙型肝炎病毒小鼠实验模型的研究进展

详细信息
  • 中图分类号: R512.63;R-332

Advance in the research of experimental mouse model for hepatitis C virus

  • 摘要:

    丙型肝炎病毒(HCV)感染是导致慢性肝病的主要原因。大部分HCV感染者呈持续性感染,这与肝硬化和肝细胞癌紧密相关。近十年来,许多学者通过不懈的努力建立了各种行之有效的小鼠实验模型,基于这些模型的研究极大地丰富和加深了对HCV感染、致病、免疫等方面分子机理的认识,同时也极大地促进了新的抗病毒策略和特异药物筛选的发展。本文就目前最常见和未来有应用前景的两类小鼠实验模型作一综述。

     

  • [1]Wu GY, Konishi M, Walton CM, et al.A novel im-munocompetent rat model of HCV infection and hepatitis[J].Gastroenterology, 2005, 128 (5) :1416-1423.
    [2]Galun E, Burakova T, Ketzinel M, et al.Hepatitis C virus viremia in SCID-BNX mouse chimera[J].J Infect Dis, 临床肝胆病杂志2011年第27卷第1期1995, 172 (1) :25-30.
    [3]Maeda N, Watanabe M, Okamoto S, et al.Hepatitis C virus infection in human liver tissue engrafted in mice with an infectious molecular clone[J].Liver Int, 2004, 24 (3) :259-267.
    [4]Mercer DF, Schiller DE, Elliott JF, et al.Hepatitis C virus replication in mice with chimeric human livers[J].Nat Med, 2001, 7 (8) :927-933.
    [5]Walters KA, Joyce MA, Thompson JC, et al.Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model:role of the innate antiviral immune response[J].PLoS Pathog, 2006, 2 (6) :e59.
    [6]Turrini P, Sasso R, Germoni S, et al.Development of humanized mice for the study of hepatitis C virus infection[J].Transplant Proc, 2006, 38 (4) :1181-1184.
    [7]Vanwolleghem T, Bukh J, Meuleman P, et al.Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain[J].Hepatology, 2008, 47 (6) :1846-1855.
    [8]Law M, Maruyama T, Lewis J, et al.Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge[J].Nat Med, 2008, 14 (1) :25-27.
    [9]Meuleman P, Hesselgesser J, Paulson M, et al.Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo[J].Hepatology, 2008, 48 (6) :1761-1768.
    [10]Moriishi K, Mochizuki R, Moriya K, et al.Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis[J].Proc Natl Acad Sci U S A, 2007, 104 (5) :1661-1666.
    [11]Kamegaya Y, Hiasa Y, Zukerberg L, et al.Hepatitis C v-irus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis[J].Hepatology, 2005, 41 (3) :660-667.
    [12]Frelin L, Brenndorfer ED, Ahlen G, et al.The hepatitis C virus and immune evasion:non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor alpha mediated liver disease[J].Gut, 2006, 55 (10) :1475-1483.
    [13]Ahéln G, Derk E, Weiland M, et al.Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes[J].Gut, 2009, 58 (4) :560-569.
    [14]Wang AG, Lee DS, Moon HB, et al.Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice[J].J Pathol, 2009, 219 (2) :253-262.
    [15]Kriegs M, Bürckstümmer T, Himmelsbach K, et al.The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo[J].J Biol Chem, 2009, 284 (41) :28343-28351.
    [16]Masciopinto F, Freer G, Burgio VL, et al.Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection[J].Virology, 2002, 304:187-196.
    [17]Ploss A, Evans MJ, Gaysinskaya VA, et al.Human occ-ludin is a hepatitis C virus entry factor required for infection of mouse cells[J].Nature, 2009, 457 (7231) :882-886.
    [18]Ploss A, Rice CM.Towards a small animal model for hepatitis C[J].EMBO Rep, 2009, 10 (11) :1220-1227.
    [19]Bitzegeio J, Bankwitz D, Hueging K, et al.Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors[J].PLoS Pathog, 2010, 6 (7) :e1000978.
    [20]Legrand N, Ploss A.Humanized mice for modeling hu-man infectious disease:challenges, progress, and outlook[J].Cell Host Microbe, 2009, 6 (1) :5-9.
    [21]Strowig T, Gurer C, Ploss A.Priming of protective T cell responses against virus-induced tumors in mice with human immune system components[J].J Exp Med, 2009, 206 (6) :1423-1434.
    [22]Wakita T, Taya C, Katsume A, et al.Efficient conditional transgene expression in hepatitis C virus cDNA transgenic mice mediated by the Cre/loxP system[J].J Biol Chem, 1998, 273 (15) :9001-9006.
    [23]Satoh K, Takahashi H, Matsuda C, et al.Natural killer cells target HCV core proteins during the innate immune response in HCV transgenic mice[J].J Med Virol, 2010, 82 (9) :1545-1553.
    [24]Stieger K, Belbellaa B, Le Guiner C, et al.In vivo gene regulation using tetracycline-regulatable systems[J].Adv Drug Deliv Rev, 2009, 61 (7-8) :527-541.
  • 加载中
计量
  • 文章访问数:  2549
  • HTML全文浏览量:  9
  • PDF下载量:  1336
  • 被引次数: 0
出版历程
  • 出版日期:  2011-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回